Big Pharma Split Corp.

QUARTERLY PORTFOLIO DISCLOSURE

as at September 30, 2021

Total Assets

The total assets of the Big Pharma Split Corp. was \$32,098,461 and includes the value of the Preferred Shares.

Summary of Investment Portfolio

Sector Allocation	% of Total Assets
Pharmaceuticals	76.5
Biotechnology	18.5
Total Portfolio Assets	95.0
Cash and other assets and liabilities	5.4
Foreign currency forwards	(0.4)
Total Asset Value	100.0

Portfolio Allocation	% of Total Assets
Common Shares	66.0
ADRs	29.5
Equity options	(0.5)
Total Portfolio Assets	95.0
Cash and other assets and liabilities	5.4
Foreign currency forwards	(0.4)
Total Asset Value	100.0

Portfolio Breakdown

Top Holdings	% of Total Assets
AstraZeneca PLC	11.1
Merck & Co., Inc.	10.0
AbbVie Inc.	9.7
Johnson & Johnson	9.6
Pfizer Inc.	9.6
Sanofi S.A.	9.4
Eli Lilly and Company	9.2
Bristol-Myers Squibb Company	9.1
Novartis AG	9.0
Amgen Inc.	8.8
Cash and other assets and liabilities	5.4
Foreign currency forwards	(0.4)
Equity options	(0.5)

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. This quarterly update is available on our website at www.harvestportfolios.com.

 Customer Service
 Address

 610 Chartwell Road

 416.649.4541
 Suite 204

 Toll: 1.866.998.8298
 Oakville, ON

 L6J 4A5

